Skip to main content
Caplight Logo









SHY Therapeutics

SHY Therapeutics

Private
Valhalla, New YorkHealthcare & Life Scienceshttps://www.shytherapeutics.com/

Last Round

Grant

Jan 6, 2025

Total Funding Raised

$300,616

Company Overview

SHY Therapeutics is a biotechnology company that develops small molecule therapeutics targeting ATPases and GTPases for the treatment of cancer and infectious diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

biotechnologydrug discoverysmall molecule therapeuticsoncologyproteasome inhibitorbiotech startupclinical-stage biotechKRas inhibitordrug developmentin-silico drug discoveryAI-driven drug discoverystructure-activity relationshipSARpharmaceutical R&Dbiotech pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

SHY Therapeutics Comparables

Compare SHY Therapeutics with similar companies based on industry and business-model similarity.

SHY Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Up Therapeutics
85%
Kestrel Therapeutics
80%
QLi5 Therapeutics GmbH
80%

SHY Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJan 6, 2025
AcceleratorNov 10, 2015

SHY Therapeutics Investors

Notable investors and investment history

SHY Therapeutics investors
InvestorRounds
National Institute of Allergy and Infectious DiseasesGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 3, 2025

    Monthly visitors increased 1730% MoM, from 30 to 549.

  • May 2, 2025

    Monthly visitors grew 705% MoM.

SHY Therapeutics Filings

Explore SEC and related filing metadata, where available.

SHY Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about SHY Therapeutics's valuation, stock price, and market status.

Is SHY Therapeutics a public or private company?

SHY Therapeutics is a private company.

What is the current stock price of SHY Therapeutics?

SHY Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is SHY Therapeutics worth (valuation)?

Valuation information for SHY Therapeutics is not publicly available.

Can I buy SHY Therapeutics stock?

SHY Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was SHY Therapeutics's last funding round?

SHY Therapeutics's most recent funding round was Grant on January 6, 2025.

Who are the main investors in SHY Therapeutics?

Key investors in SHY Therapeutics include National Institute of Allergy and Infectious Diseases.

Will SHY Therapeutics IPO soon?

No public IPO plans have been announced for SHY Therapeutics.

How can I track SHY Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor SHY Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersValhalla, New York
Year Founded2015
Last FundingJan 6, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?